CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Coexpression of IL15 Promotes Effector Differentiation and Sustained Proliferative Capacity in ALPPL2-Specific Human CAR T Cells.
Coexpression of IL15 Promotes Effector Differentiation and Sustained Proliferative Capacity in ALPPL2-Specific Human CAR T Cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体 (CAR) T 细胞对血液系统恶性肿瘤具有强效抗肿瘤活性,并具有使实体瘤患者获益的潜力。对过继转移 T 细胞中表达的鼠源蛋白的免疫识别,以及肿瘤微环境中稳态细胞因子的缺乏,可限制 CAR-T 细胞的扩增和持久性。仅由人源序列生成的 CAR 可降低免疫介导排斥反应的风险,而白细胞介素 15 (IL15) 可促进 T 细胞存活和功能适应性,可能改善 CAR-T 细胞的扩增和持久性。
在本研究中,我们报告了一种由人源序列组装而成的 CAR 构建体 (ABBz),其中包含特异性针对碱性磷酸酶、胎盘样 2 (ALPPL2) 的单链可变片段 (scFv)。该结合物是通过对人抗体来源的噬菌体展示 scFv 文库进行无偏、高通量筛选,基于结合特异性、严格性和低解离常数选出的。
我们在 ABBz T 细胞中证明了针对抗原的特异性、有效的溶细胞功能和细胞因子产生。我们显示,在 ABBz T 细胞中,分泌型 IL15 共表达特异性地诱导了具有持续增殖能力的 NK 样效应分化。
最后,我们证明 ABBz CAR-T 细胞具有强效抗肿瘤活性,该活性通过 IL15 共表达进一步增强,导致 NK 样效应分化,具有增强的细胞毒性,并因 CAR-T 细胞凋亡减少而具有更优的扩增能力。这些结果表明,IL15 共表达可促进效应分化,同时维持 huALPPL2-CAR-T 细胞的增殖能力,并为 IL15 共表达 huALPPL2-CAR-T 细胞在患者中的进一步临床开发提供基础。
Chimeric antigen receptor (CAR) T cells have robust antitumor activity against hematologic malignancies and have the potential to benefit patients with solid tumors. Immune recognition of murine proteins expressed in adoptively transferred T cells and the lack of homeostatic cytokines in the tumor microenvironment can limit the expansion and persistence of CAR T cells. CARs generated only from human sequences could reduce the risk of immune-mediated rejection, and interleukin 15 (IL15), which promotes T-cell survival and fitness, may improve the expansion and persistence of CAR T cells.
In this study, we report a CAR construct (ABBz) assembled from human sequences including a single-chain variable fragment (scFv) specific to alkaline phosphatase, placental-like 2 (ALPPL2). This binder was selected through an unbiased, high-throughput screen of a human antibody-derived, phage-displayed scFv library based on binding specificity, stringency, and low dissociation constant.
We demonstrated specificity to the antigen, effective cytolytic function, and cytokine production in ABBz T cells.
We showed NK-like effector differentiation with sustained proliferative capacity specific to secreted IL15 coexpression in ABBz T cells. Lastly, we demonstrated that ABBz CAR T cells had robust antitumor activity, which was further enhanced through IL15 coexpression, resulting in NK-like effector differentiation with increased cytotoxicity and superior expansion capacity due to reduced apoptosis of CAR T cells.
These results demonstrate that IL15 coexpression can promote effector differentiation while maintaining the proliferative capacity of huALPPL2-CAR T cells and provide a foundation for further clinical development of IL15-coexpressing huALPPL2-CAR T cells in patients.
MEMBER ACCOUNT
登录成功会直接打开下一页。